Enzymotec (ENZY) Tops Q3 EPS by 1c; Guides FY15 EPS Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
Enzymotec Ltd. Reports Third Quarter 2015 Results
November 11, 2015 7:30 AM ESTEarns non-GAAP $0.08 and GAAP $0.07 per Diluted Share and Generates $4.7 Million in Operating Cash Flow
VAYA Pharma Generates Record Net Revenues of $2.2 Million
MIGDAL HA'EMEQ, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported financial results for the third quarter ended September 30, 2015.
Third Quarter Financial Highlights
Third quarter net revenues (equity method) increased 30.7% to $12.4 million, compared to the third quarter of 2014. Third quarter net revenues (proportionate... MoreEnzymotec Ltd. Reports Third Quarter 2015 Results
November 11, 2015 7:30 AM ESTEarns non-GAAP $0.08 and GAAP $0.07 per Diluted Share and Generates $4.7 Million in Operating Cash Flow
VAYA Pharma Generates Record Net Revenues of $2.2 Million
MIGDAL HA'EMEQ, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported financial results for the third quarter ended September 30, 2015.
Third Quarter Financial Highlights
Third quarter net revenues (equity method) increased 30.7% to $12.4 million, compared to the third quarter of 2014. Third quarter net revenues (proportionate... More